News | April 10, 2013

CardioFocus Announces 1,000 HeartLight Cases Performed Worldwide

Company convened expert symposium in Boston to discuss clinical experiences

 

April 10, 2013 β€” CardioFocus Inc. announced that as of late 2012, more than 1,000 clinical cases have been performed worldwide using the HeartLight technology. The company hosted an expert symposium to review the clinical application of HeartLight and key observations made during the first 1,000 cases in January.

Prof. Karl-Heinz Kuck, M.D. of Asklepios Klinik St. Georg, Hamburg, Germany, and co-chair of the symposium, said, "Our clinical experience has demonstrated that the HeartLight technology possesses unique capabilities for the treatment of AF. Notably, it allows physicians the ability to directly see the tissue to be ablated, and offers a laser energy source to facilitate the creation of durable lesions irrespective of contact force. My colleagues and I have had the opportunity to evaluate its promising clinical impact, collect and analyze the data, and, now, further refine our technique to give patients the best chance of achieving freedom from AF."

Presentations focused on topics including techniques for utilizing the endoscopically-guided ablation system, the desired location of pulmonary vein isolation and the impact of HeartLight laser energy titration on achieving durable results. There was also a discussion of clinical results obtained using HeartLight in comparison to systems using alternative energy sources. In addition to Kuck, the event was co-chaired by Andrea Natale, M.D. of Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Austin, Texas, and Vivek Y. Reddy, M.D., of Mt. Sinai University Medical Center, New York, N.Y.

HeartLight is the first catheter ablation system to incorporate an endoscope, a laser energy source and a compliant balloon catheter to enable direct visualization of the beating heart during catheter ablation. The system is CE marked and clinically available in Europe and Australia. In the United States, it is investigational and currently the focus of an ongoing multi-center pivotal trial.

For more information, please visit www.CardioFocus.com


Related Content

News

July 14, 2025  –  Johnson & Johnson MedTech has announced U.S. Food and Drug Administration (FDA) approval of an update ...

Home July 14, 2025
Home
News

July 7, 2025 β€” Catheter ablation is a minimally invasive treatment for abnormal heart rhythms. It is often successful in ...

Home July 09, 2025
Home
News

June 4, 2025 β€” A new study published in The Annals of Thoracic Surgery, a journal from The Society of Thoracic Surgeons ...

Home June 04, 2025
Home
News

April 24, 2025 – The Heart Rhythm Society (HRS) and the American College of Cardiology (ACC) have released a scientific ...

Home April 24, 2025
Home
News

April 9, 2025 β€” Merit Medical Systems has announced the U.S. commercial release of its Ventrax Delivery System. Ventrax ...

Home April 16, 2025
Home
News

March 27, 2025 β€” Abbott recently announced it has received CE Mark in Europe for the Volt PFA System to treat patients ...

Home March 27, 2025
Home
News

Oct. 24, 2024 β€” Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera ...

Home October 30, 2024
Home
News

Oct. 18, 2024 β€” Boston Scientific Corp. recently announced it has received U.S. Food and Drug Administration (FDA) ...

Home October 21, 2024
Home
News

May 15, 2024 β€”CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac ...

Home May 15, 2024
Home
News

May 13, 2024 β€” Innovative Health, Inc. announced that recent growth in single-use device reprocessing has delivered ...

Home May 13, 2024
Home
Subscribe Now